Roundhill Innov-100 0DTE Covered Call Strat ETF vs Stryker Corporation — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.65, while Stryker Corporation trades at $276.5 (market cap $106.03B). The key difference: Stryker Corporation pays a 1.27% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| QDTE | SYK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $36.60 | $388.79 |
52-Week Low | $26.85 | $275.39 |
Market Cap | — | $106.03B |
Enterprise Value | — | $117.50B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $28.86 with minimal daily movement (+0.07%). The ETF shows bearish technical signals with selling pressure outweighing buying signals 12-4. Recent news highlights concerns about the fund's sustainability as volatility declines and distributions are funded by return of capital, causing NAV erosion. The fund's 0.97% expense ratio consumes significant portions of its weekly payouts.
The outlook remains cautious given structural concerns about the fund's distribution model. While weekly income appeals to investors, the erosion of net asset value and dependence on return of capital present significant risks. Analyst sentiment has turned negative with recent downgrades citing underperformance in bull markets and unsustainable yield mechanics.
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Trailing returns across standard periods
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →